Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease, Nephrology |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/13/2019 |
| Start Date: | April 23, 2018 |
| End Date: | July 31, 2019 |
Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict Acute Kidney Injury in Children Research Multiple Nephrotoxic Medications
Nephrotoxic medication (NTMx) exposure is one of the most commonly cited causes of acute
kidney injury (AKI) in hospitalized children, and is the primary cause of AKI in 16% of
cases. Through initial work at Cincinnati Children's Medical Center, NTMx exposure was found
to be potentially modifiable and the associated AKI is an avoidable adverse safety event.
Currently, only serum Creatinine monitoring is available to monitor for NTMx-associated AKI.
The hypotheses of this NINJA NGAL study are that (1) urine NGAL is highly sensitive to detect
NTMx-associated AKI, and (2) Bedside test of urine from high risk NTMx-exposed patients are
adequate and reliable compared to urine NGAL measured from the clinical platform.
kidney injury (AKI) in hospitalized children, and is the primary cause of AKI in 16% of
cases. Through initial work at Cincinnati Children's Medical Center, NTMx exposure was found
to be potentially modifiable and the associated AKI is an avoidable adverse safety event.
Currently, only serum Creatinine monitoring is available to monitor for NTMx-associated AKI.
The hypotheses of this NINJA NGAL study are that (1) urine NGAL is highly sensitive to detect
NTMx-associated AKI, and (2) Bedside test of urine from high risk NTMx-exposed patients are
adequate and reliable compared to urine NGAL measured from the clinical platform.
Inclusion Criteria:
- Receiving 3 or more nephrotoxic medications on the same day OR
- Receiving 3 or more days of an intravenous aminoglycoside or vancomycin
Exclusion Criteria:
- Currently being treated for a urinary tract infection
- Presence of an acute kidney injury prior to enrollment
We found this trial at
2
sites
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
Cincinnati, Ohio 45229
1-513-636-4200
Principal Investigator: Stuart Goldstein, MD
Phone: 513-636-4837
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
Click here to add this to my saved trials
Click here to add this to my saved trials